Skip to main content

Advertisement

Table 2 General characteristics of general practitioner (GP) evaluators of abstracts of randomized controlled trials of pharmaceutical treatments

From: Reporting funding source or conflict of interest in abstracts of randomized controlled trials, no evidence of a large impact on general practitioners’ confidence in conclusions, a three-arm randomized controlled trial

GP characteristics All GPs number = 354 Abstracts with no mention of funding source or CoI number = 118 Abstracts reporting funding source only number = 118 Abstracts reporting funding source and CoI number = 118
Gender (male) - number (%) 227 (64.9) 78 (66.7) 76 (65.5) 73 (62.4)
Age, years - median (Q1 to Q3) 51.4 (36.4; 57.3) 48.7 (37.1; 56.3) 51.8 (36.2; 57.6) 52.7 (37.4; 57.2)
Receive fees from pharmaceutical industry - number (%) 75 (21.6) 30 (26.3) 20 (17.1) 25 (21.6)
    For performing a presentation 22 (6.3) 8 (7.0) 7 (6.0) 7 (6.0)
    For consulting 16 (4.6) 4 (3.5) 6 (5.1) 6 (5.2)
    For enrolling patients in a trial 60 (17.3) 26 (22.8) 18 (15.4) 16 (13.8)
Participate (current or past) in a trial funded by pharmaceutical industry – number (%) 151 (43.5) 54 (47.4) 47 (40.2) 50 (43.1)
Receive visits from medical representatives of pharmaceutical industry - number (%)     
    None 174 (50.1) 56 (49.1) 59 (50.4) 59 (50.9)
    1 to 5 per month 84 (24.2) 30 (26.3) 25 (21.4) 29 (25.0)
    6 to 10 per month 54 (15.6) 17 (14.9) 21 (17.9) 16 (13.8)
    >10 per month 35 (10.1) 11 (9.6) 12 (10.3) 12 (10.3)
  1. CoI, conflicts of interest.